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Summary 
 
Neurodevelopmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD) and 
Autism Spectrum Disorder (ASD), although most commonly considered in childhood, can be 
life-long conditions. In this personal perspective that is shaped by clinical experience as well 
as research, we adopt a conceptual approach. First we discuss what disorders are 
neurodevelopmental and why such a grouping is useful. We conclude that both distinction 
and grouping are helpful and that it is important to take into account the strong overlap 
across neurodevelopmental disorders. Then, we highlight some challenges in bridging 
research and clinical practice. We discuss the complexity of clinical phenotypes, the 
importance of the social context and consider developmental change across the life-span. 
Finally we argue the importance of viewing neurodevelopmental disorders as traits but 
highlight that this is not the only approach to use. Overall, we argue strongly for a flexible 
approach in clinical practice that takes into consideration the high level of heterogeneity 
and overlap in neurodevelopmental disorders and for research to link more closely to what 
is observed in real-life practice.  
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Search strategy and selection criteria 
This article is a personal perspective and not a review; the authors identified papers according 
to their relevance to the conceptual issues being discussed. Papers published were first 
identified by searches of PubMed from 1st January 2010 to 31st March 2016 using the search 
teƌŵs ͞ADHD͟, ͞autisŵ͟, ͞A“D͟, ͞ĐoŵŵuŶiĐatioŶ͟, ͞laŶguage͞, ͞ƌeadiŶg͟, ͞spelliŶg͟, ͞tiĐs͟ 
AND ͞Đhild͟, ͞adult͟, ͞loŶgitudiŶal͟, ͞ĐoŵoƌďiditǇ͟, ͞ŵultiŵoƌďiditǇ͟, ͞geŶetiĐ͟, ͞pƌeŶatal͟, 
͞aetiologǇ͟. Only articles published in English were included.    Reviews on 
neurodevelopmental disorders, book chapters and NICE guidelines published between 1st 
January 2012 and 2016 and some older articles were also examined. Systematic reviews on 
ADHD and autism are published elsewhere.  
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Neurodevelopmental disorders are complex conditions that are far from straightforward to 
conceptualise.  In this personal perspective article, we discuss some key issues for clinicians 
and scientists to consider. Our views have been shaped by clinical practice as well as by 
research and the intention of this article is to offer our perspective on neurodevelopmental 
disorders.  
What we mean by neurodevelopmental disorder 
The teƌŵ ͚ŶeuƌodeǀelopŵeŶtal͛ has ďeeŶ applied to a ǀeƌǇ ďƌoad gƌoup of disaďilities 
involving some form of disruption to brain development. This definition groups together a 
very wide range of neurological and psychiatric problems that are clinically and 
aetiologically disparate; for example, rare genetic syndromes, cerebral palsy, congenital 
neural anomalies, schizophrenia, autism, attention deficit hyperactivity disorder (ADHD) and 
epilepsy. In our view, whilst it is important to recognise the importance of early and life-long 
developmental processes for health problems, an overly broad approach to grouping 
neurodevelopmental disorders becomes unhelpful1,2.  
In this article, we adopt the approach of DSM-53 that groups ADHD, Autism Spectrum 
Disorder (ASD), Intellectual Disability, Communication Disorders, Specific Learning Disorders 
and Motor Disorders (e.g. developmental co-ordination disorder and tic disorders) as 
͞Neurodevelopmental Disorders͟ . Whilst we are not enthusiastic about all aspects of DSM-
5, as discussed previously4 this approach to grouping neurodevelopmental disorders is a 
useful one for a variety of reasons2.  
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Why group neurodevelopmental disorders?   
What is the rationale for such a grouping? 
One of the key defining characteristics of these neurodevelopmental disorders is that they 
typically onset in childhood, prior to puberty.  They are also distinguished from many 
neuropsychiatric disorders in respect to their clinical course: despite being subject to 
maturational changes, neurodevelopmental disorders such as ADHD, ASD, intellectual 
disability, learning and communication disorders tend to show a steady course rather than 
the remitting and relapsing pattern that commonly characterises post-pubertal mood 
disorders and schizophrenia. These disorders are also characterised by prominent early-
onset neurocognitive deficits and they more commonly affect males5. Although highly 
heritable6, neurodevelopmental disorders are typically multi-factorial in origin; single major 
causes are rare (e.g. foetal alcohol syndrome, genetic syndromes) and such forms of 
disorder are classified elsewhere2. Finally, the level of overlap between these disorders and 
their constituent symptom dimensions is very high. This further supports the rationale for 
considering them together. As is true of all classification systems and diagnostic groupings, 
neurodevelopmental disorders are highly heterogeneous in terms of their clinical 
characteristics, aetiology, treatment response and outcomes; there is no specific clinical or 
biological characteristic that clearly distinguishes this grouping from other neuropsychiatric 
disorders. For example, tic disorders do not tend to show a steady course and ADHD can 
remit in some. Schizophrenia and early-onset conduct disorder are commonly characterised 
by early cognitive and developmental impairments but are grouped elsewhere in DSM 5 
(see elsewhere2 for further discussion of these points). 
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Nevertheless, the early age of onset and high level of overlap means that grouping 
neurodevelopmental disorders in this way is also clinically useful. Assessment and treatment 
expertise for children with these disorders crosses disciplines (e.g. child psychiatrist, 
psychologist, paediatrician, speech and language therapist, occupational therapist) as well 
as agencies (e.g. health and education) and can be fragmented (Figure 1). To provide one 
example, in the UK  a child typically requires assessment for ADHD in a child mental health 
or paediatric service; co-occuring reading disability is the domain of education services, 
motor co-ordination problems need to be assessed by an occupational therapist and 
language/social communications difficulties are the specialist domain of speech and 
language therapists.  Many of these professionals are based in different services and local 
assessment and treatment provision are organised around a single diagnosis (e.g. ADHD or 
ASD7) in a number of countries. If co-occurrence of neurodevelopmental disorders is the 
rule rather than the exception in clinical practice2, then grouping professional expertise, 
services and resources for children with these problems as part of a neurodevelopmental 
hub of expertise can help ensure assessment and intervention across all 
neurodevelopmental domains and explicitly recognise the overlaps.  
Why it is important to retain diagnostic distinctions  
Although grouping is useful, it remains necessary to recognise important distinctions 
between different neurodevelopmental disorders. For example, the differential effects of 
medication highlight that despite overlaps, neurodevelopmental disorders are not 
biologically or clinically identical sets of problems. While stimulant medication8 and 
atomoxetine9 alleviate symptoms of ADHD and atypical antipsychotics can reduce severe 
tics10, none of these medications impact on core features of the other neurodevelopmental 
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disorders. Distinct diagnostic categories, also provide a means for clinicians to readily 
ĐoŵŵuŶiĐate patieŶts͛ diffiĐulties ǁith eaĐh otheƌ aŶd ǁith patieŶts theŵselǀes. Thus there 
is a clear indication to retain the practice of distinguishing these disorders as well as 
grouping them. 
 
Neurodevelopmental disorders are more than their defining symptoms  
Disaggregating individual clinical profiles  
Historical tradition has influenced the defining features of many neurodevelopmental 
disorders and some of the decisions as to what to include might be considered arbitrary. 
Phenotypically, neurodevelopmental disorders are more than a defining set of symptoms 
and extend beyond the boundaries of a neurodevelopmental group. Indeed Kanner, in his 
1969 article on differential diagnosis 11, highlighted the tendency to pigeonhole patients into 
a category rather than really understand them - ͞that ĐhildƌeŶ had Ŷot ƌead the ƌight ďooks͟ 
when it came to diagnosis. If we take ADHD as the example here, relevant, common ADHD 
profiles (see Figure 2) include not only its defining symptoms (hyperactive-impulsiveness, 
inattention) and features of other neurodevelopmental disorders but also additional 
cognitive deficits such as impaired working memory and planning12,13. Equally, emotional 
features involving mood lability and irritability used to be considered an integral aspect of 
ADHD14 but would now be considered as part of a co-occurring disorder (e.g. anxiety, 
depression or oppositional defiant disorder). The overlap of ADHD with conduct problems is 
also prominent15. Some of these symptom profiles will be recognised as an additional 
diagnosis. However if symptoms do not achieve the threshold for a diagnosis, they will not 
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be captured for the purpose of either research or clinical practice; the clinical implications of 
sub-threshold symptoms will be discussed later in this article.  
The same historical tradition has influenced diagnostic exclusion criteria. For example, it has 
long been appreciated that the autistic spectrum includes children with intellectual 
disability, but in the case of ADHD, the absence of intellectual disability (ID) was highlighted 
as important16. However, this assumption is now recognised to be invalid, and the practice 
of failing to diagnose ADHD in the presence of ID is starting to change17,18.   
The finding that those exposed to early, severe privation displaǇ featuƌes of ͞Ƌuasi-
autisŵ͟19 provides an illustrative case of how disorders may present in an unusual fashion in 
an atypical social context. This highlights the importance of why assessments of 
phenomenology need to extend beyond core diagnostic criteria and the constraints of a 
structured interview. However in clinical settings, assessments will typically extend beyond 
diagnostic items and most would accept the importance of assessing social context and 
takiŶg iŶto aĐĐouŶt aŶ iŶdiǀidual͛s ĐuƌƌeŶt ͞ƌesouƌĐes͟ ;e.g. ĐogŶitiǀe aďilitǇ, ƋualitǇ of 
paƌeŶtiŶg, iŶĐoŵeͿ aŶd ͞deŵaŶds͟ ;e.g. Đlassƌooŵ eŶǀiƌoŶŵeŶtͿ, as well as their level of 
functioning, in order to devise a comprehensive management plan.  
Gaps between research and clinical practice need to be bridged. Our view is that 
observation and clinical insights remain valuable for informing research questions. Also,  
research participants need to be characterised beyond a single core diagnosis; for example 
by assessing participants across multiple dimensions of symptoms, functioning and social 
contexts, regardless of primary diagnosis. A shared measurement tool kit used by different 
health-care professionals and researchers might be helpful here. 
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Why are profiles beyond core diagnostic features relevant? 
Selecting appropriate treatments: First, for clinicians, different problem areas may require 
different sorts of evidence-based treatments that would not be captured by treatment 
guidelines for a single neurodevelopmental disorder; for example cognitive behavioural 
strategies (CBT) for anxiety20 and parenting interventions for behaviour problems21. 
Secondly, aŶ iŶdiǀidual͛s sǇŵptoŵ pƌofile aĐƌoss ŵultiple diŵeŶsioŶs ĐaŶ pƌoǀide a useful 
prognostic index.  Co-occurrence rates of problems and disorders are elevated in clinics - so 
Đalled BeƌksoŶ͛s ďias. This selection is unsurprising given that those with problems in 
multiple disorder domains are more severely impaired in terms of outcomes22. 
Predicting outcomes: What sorts of co-occurring problems index a poorer outcome? One 
possibility is that it is the consequence of the total burden of childhood problems regardless 
of the nature of psychopathology. Copeland and colleagues 23 addressed this using the 
Great Smoky Mountains longitudinal study. These investigators found that the cumulative 
childhood burden of psychopathology was the best predictor of adult health (e.g. 
addictions, suicidality, serious physical illness), legal (e.g. criminal act), financial (e.g. unable 
to keep job) and social outcomes (e.g. no social support), even allowing for adult 
psychopathology and childhood psychosocial adversity. In a more recent UK population-
based study, the total childhood burden of neurodevelopmental and conduct problems 
predicted a persistent ADHD symptom trajectory to adolescence.  
Other evidence highlights that different symptom profiles show specificity in relation to the 
type of later psychopathology and functional outcome24,25. For example, in a Swedish study 
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of multiple neurodevelopmental problems26 childhood ADHD predicted adolescent 
antisocial behaviour and impaired functioning independent of other neurodevelopmental 
problems. A systematic review of longitudinal ASD studies, highlighted that child IQ and 
early language ability appear to be the strongest predictors of ASD outcome27. The degree 
to which later functional and psychiatric outcomes of neurodevelopmental disorders are 
predicted by specific symptom profiles and/or the total burden of problems needs further 
investigation, as do the biological/social mechanisms that explain variation in outcomes. 
Longitudinal studies that span from childhood to adult-life are required to address such 
questions.  
Multi-morbidity in clinical practice 
The concept of multi-morbidity acknowledges the clinical importance of multiple problems 
in a single individual. Multi-morbidity is commonly defined as the presence of two or more 
chronic conditions in the same individual and is now a major concern in general 
medicine/primary care. That is because of growing recognition that multi-morbidity is 
common and has important clinical and service implications (Barnett et al, 2012) 
(https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0704).  
 Fragmented service provision is one problem for patients with multi-morbidity. Clinical 
pathways which focus explicitly on the diagnostic process of one condition alone may be 
missing salient features of other disorders. Another is that assessment and treatment 
guidelines, including those relevant for ADHD and ASD7,28  typically focus on a single 
disorder, yet treatment needs as well as prognosis might be altered in the presence of other 
disorders.  
  
11 
How might treatment be affected? First, the threshold for treating one condition might be 
altered by the presence of other conditions (e.g. in the presence of certain conditions 
including renal disease and diabetes, the threshold for treating hypertension is lower)29. 
Second, the effectiveness of a recommended treatment for the primary condition might be 
moderated by the presence of other conditions. This has not been widely investigated for 
child psychopathology although there are some exceptions20,30. For example, in the case of 
ADHD, behavioural interventions appear to be especially helpful for those with anxiety30 and 
although stimulants reduce ADHD symptoms in those with intellectual disability or ASD, 
medication is less well-tolerated 31,32. At present, we have limited evidence on how clinical 
management might be altered in the context of neurodevelopmental multi-morbidity; for 
example should the threshold for providing intervention for communication impairments or 
ASD be lowered in the presence of ADHD? Typically, the diagnostic process is hierarchical 
and parsimonious and sometimes that is helpful because it simplifies the key issues and can 
help focus on the predominant features. However it is being increasingly recognised that 
using a hierarchical approach and exclusion criteria can be problematic because important 
features beyond the diagnosis of primary interest might not be assessed and treated or 
considered in research studies; for example, prior to DSM-5, ADHD could not be diagnosed 
in the presence of ASD33. This has meant that many research studies did not assess both 
phenotypes or excluded those with both conditions until this notion began to be 
challenged34. Future intervention and outcome research on individuals with multiple 
neurodevelopmental problems would be helpful in addressing this knowledge gap. 
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Neurodevelopmental disorders conceptualised as traits 
Evidence that neurodevelopmental disorders behave as traits  
There is strong research evidence that favours considering some neurodevelopmental 
disorders/diagnoses as lying at the extremes of dimensions13,35,36.  For example,  ADHD 
defined as a trait, typically using total symptom scores, behaves dimensionally in terms of its 
relationship with adverse outcomes 37 - there is no clear-cut threshold beyond which 
adverse outcomes emerge. Also, the same genetic and early environmental risk factors that 
are associated with a diagnosis of ADHD or ASD predict  trait levels in the general population 
38–42.  However categorical conceptualisation can be helpful for some purposes4; for 
example when dichotomous and potentially risky clinical decisions, such as whether to 
prescribe medication for a child or not, have to be made.  
Where does the cut-point on a dimension lie?  
This question is not straightforward to address because it depends on what the cut-point is 
required for. In general for child psychopathology, sub-threshold diagnoses (fewer 
symptoms but impairment) are common and are clinically important in terms of predicting 
poorer adult mental health and function outcomes23. However expanding diagnoses is 
unhelpful because there are potential social, psychological and health risks 43 as well as 
benefits of applying a diagnostic label and providing treatments.  For example, NICE 
guidance for ADHD28 applies a lower threshold for psychosocial intervention than for 
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medication and recommends a step-wise treatment approach13 but that does not deal with 
the public health issue of sub-threshold cases of any neurodevelopmental disorder.  
What is the dimension?  
Another question is how should one define the underlying dimension given a diagnosis is 
more than just one trait? For example, ADHD symptom scores are highly correlated with 
many other traits, so a diagnosis of ADHD might not even be best conceptualised as lying at 
the extreme of a single measured ADHD trait (i.e. total ADHD symptom count) but rather as 
being underpinned by multiple trait as well as biological liabilities44,45. 
Alternatives to a traditional categorical diagnostic approach are being considered in the 
context of research. The Research Domain Criteria (R-DoC) project is one such research 
framework proposed by the NIMH 46. It has been proposed as a means of investigating 
mental disorders by conceptualising them as dimensional constructs (e.g. negative valence 
systems) (http://www.nimh.nih.gov/research-priorities/rdoc/constructs/rdoc-matrix.shtml) 
which transcend diagnostic categories and  integrate information across multiple 
measurement levels (e.g. genes, molecules, cells, circuits as well as self-reports). Whilst a 
dimensional framework is to be welcomed, and will be helpful for some types of research 
e.g. bridging basic science and human cognitive and imaging research47, as yet we do not 
have reliable methods for assessing many of the suggested R-doc dimensions and nor do we 
know how they map onto complex, clinically relevant problems. It is important that this gap 
is spanned if research is going to inform clinical practice and clinical observations are to 
inform basic research.  
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Consideration of developmental change and a life-span approach 
Symptom decline but persistence to adult life  
Neurodevelopmental disorders are subject to maturational change2. Many child 
neurodevelopmental disorders typically improve with age and previously were considered 
as childhood-limited problems. However, follow-up studies show that although outcomes 
are variable, for many individuals, neurodevelopmental problems/diagnosis do persist into 
adult life 1,48–52. Reported estimates of diagnostic persistence rates vary widely and tend to 
be higher in patient samples than in population-based cohorts53. For example, if we take the 
example of ADHD, one meta-analysis suggested a 15% ADHD diagnostic persistence rate to 
adult life 48. ASD, language impairments54 and literacy-related55 difficulties also commonly 
persist in many. Some core symptoms, for example ADHD-related hyperactive-
impulsiveness56, and ASD-related behaviours27, decline considerably with age. In recognition 
of this the required number of ADHD symptoms for a DSM-5 diagnosis of ADHD has been 
adjusted for adolescents and adults.  However service provision for neurodevelopmental 
disorders in adult life is limited57,58.  
Change in predominant manifestation  
Change does not simply involve a decline in core symptoms as the predominant clinical 
manifestations are also subject to change and new co-occurring problems (e.g. substance 
misuse) can emerge 59. For example, many who do not meet full diagnostic criteria for ADHD 
or ASD in adult life have sub-threshold persistence of core symptoms and a broader range of 
cognitive, psychiatric (e.g. mood disorder, substance misuse) and functional impairments 
such as difficulties with employment or social relationships 53,59,60. At present, there is very 
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little known about potentially modifiable factors (e.g. prenatal and early life environmental 
enrichment, social influences) that optimise neurodevelopmental outcomes and this is an 
important area for future research. Longitudinal observational designs will remain 
important but other methods then are required to test causal hypotheses (as discussed 
extensively elsewhere61). 
A life-course view 
Until recently, it has been assumed that adult symptoms of neurodevelopmental disorders 
must be a continuation from childhood-onset problems. However an intriguing recent 
finding from the Dunedin longitudinal cohort group challenges this assumption in relation to 
ADHD. Moffitt and colleagues 53 found that most cases of adult ADHD at age 38 years were 
not preceded by a childhood diagnosis. This finding has been replicated now in two 
independent adolescent/young adult samples62,63. The problems were not entirely explained 
by concurrent or earlier comorbidities. The explanation of this phenomenon being explained 
by sub-threshold cases is also unsatisfactory. The findings raise the question of what this 
adult ADHD phenotype is. Is it the manifestation of symptoms suppressed earlier in life due 
to early protective factors or does it represent a different disorder altogether with a 
different pathogenesis akin to juvenile-onset and maturity-onset diabetes? These findings 
have important implications for adult mental health services as well as for future research64. 
There is a need for detailed longitudinal characterisation of neurodevelopmental disorder 
phenotypes across ages in unselected populations to examine patterns of onset, desistence 
and persistence across the life-span. One challenge for such developmentally informative 
research is that both researchers and clinicians use different measures after age 16-18 years 
and informants typically change from parent- to self-reports in adult life. One approach that 
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might help bridge this gap between childhood and adult life is to encourage research 
investigations (and clinical services) that focus on transition ages (e.g. ages 15 to 25 years).  
 
Perspectives on how clinicians and researchers might proceed 
Adopt a conceptual approach  
Our main conclusion is that regardless of what framework is used for conceptualising 
neurodevelopmental or psychiatric disorders, there are problems if clinicians and 
researchers apply them rigidly without thought or critical reflection; for example by 
counting up items generated by a structured interview or generating a score (e.g. ADI and 
ADOS generated diagnosis of ASD). Thresholds for defining disorders, that is the numbers of 
required symptoms, are arbritary. Failing to recognising comorbidities or symptoms beyond 
the primary diagnosis of interest is another risk. Historically such an approach has caused 
problems (for example, comorbid ADHD and ASD being disallowed by DSM and ICD) for 
researchers and clinical practitioners. For example, a child might not meet the exact 
symptom cut-point for a diagnosis of ADHD but if they fall just below the diagnostic 
threshold and symptoms are interfering with functioning-then behavioural and social 
approaches typically used for ADHD might be helpful.  
It is also important to adopt a developmental view across the life-span ; this requires 
longitudinal research approaches that bridge child and adult life and a clinical perspective 
that goes beyond current presenting problems. . The clinician is required to weigh up 
multiple factors when conducting assessments, planning intervention and predicting 
outcomes (see Leckman & Taylor for details of a ͞common-sense approach͟Ϳ. Individuals 
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with the same diagnosis might require very different types of intervention depending on co-
occuring symptoms, age (e.g. an adult vs. prepubertal child), social context (e.g. low income 
single parent with mental health problems and limited support at school vs. high income, 
strongly supportive extended family, private tutoring in addition to school).  
Consider complexity vs. reductionism  
We conclude that it is clinically helpful and scientifically justified to group 
neurodevelopmental disorders but necessary also to retain diagnostic distinctions. Of 
course, we recognised there is enormous heterogeneity in symptoms, outcome and 
treatment response across all neurodevelopmental and psychiatric disorders and there are 
no clear-cut boundaries between different disorders or between different groups of 
disorders. The strong overlap and a lack of clear-water between disorders does not mean it 
is necessarily helpful to completely dispense with diagnostic boundaries or groupings. Most 
clinicians will recognise that neurodevelopmental disorders are more than a set of 
diagnostic criteria and that multiple impairments or multi-morbidity are the rule rather than 
exception. However research funders, service funding and planning, local assessment 
policies and national guidelines are not necessarily as flexible.  Interventions are not 
identical for different types of problems so it is important to capture these complex 
phenotype patterns and associated subthreshold symptoms, and consider the social context 
and developmental factors in research as well as clinical practice. This is achievable and 
there are many examples of such research, some of which we have already discussed23,65. 
Complexity is the nature of clinical problems, so perhaps it is better to acknowledge this and 
attempt its capture if the gaps between neuroscience and mental health research as well as 
between research and real-life clinical practice are ever to be bridged. Clinicians need to 
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apply clinical judgement as well as evidence and guidelines and researchers need to engage 
directly with clinicians so that research is clinically meaningful.  
A neurodevelopmental disorder diagnosis is inadequate as a means of "rationing"  
In our view, as patient expectations grow and resources diminish66, clinicians are being 
called upon to make decisions that affect resource allocation for a patient. It is not 
reasonable for services or agencies however to allocate intervention and support purely on 
the basis of a yes/no diagnosis, including ones made after lengthy, protracted and expensive 
assessments (e.g. educational support to be linked to a diagnosis of ASD). That is because an 
individual's needs are not best captured by diagnosis alone. Systematic and validated 
methods for assessing the needs of children and adults with neurodevelopmental disorders 
beyond diagnosis are needed to avoid those with subthreshold symptomatology but 
significant impairment missing out on vital service provision.  
So do we dispense with diagnosis? We think not. There are long-standing arguments in 
psychiatry disputing the validity and value of diagnosis and on lumping vs. splitting different 
forms of psychopathology as well as concerns and apologies about relying on reported 
symptoms. This is not helpful for practitioners and patients. 
For current purposes they are reasonably reliable, useful for communication and attempting 
to standardise treatment approaches provided they are used sensibly as a framework (see 
Table 1), rather than as fundamental truths; and not as the sole means of determining 
patient care.  For researchers, it is premature in our view to dispense with diagnoses but 
equally we need to empirically and critically assess the value of alternatives. 
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Table 1: Conceptualising neurodevelopmental disorders: a summary 
 
 Group and distinguish neurodevelopmental disorders 
  Disaggregate beyond core diagnostic symptoms 
 Consider overall burden of psychopathology /multi-morbidity 
  Social context (demands, resources and risks) is important 
  Take into account developmental change across the life-span and maturational influences 
  Traits and categorical diagnoses are useful 
  Unhelpful to dispense with diagnosis or rigidly adhere to them 
 
 
 
 
 
 
 
  
  
21 
Agencies that might be involved in assessment, 
treatment and follow-up 
Education                        Primary care                 Social care/voluntary 
sector 
 
 
 
Speech and Language Occupational therapy,  
Therapy     Physiotherapy 
Mental Health           Child Health 
 
 
 
Figure 1. Assessment and management of neurodevelopmental problems: the potential for 
fragmentation of services 
  
Presenting manifestation 
Scholastic 
Behavioural 
Emotional 
Social 
Communication 
Motor 
Social/family adversity and 
stress 
Physical health e.g. 
seizures 
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Common clinical profiles associated with ADHD: where disaggregating a single diagnosis can be 
helpful 
 
 
 
 
 
 
 
 
 
 
 
   
  
  
 
The effectiveness of simultaneous interventions for the total profile of difficulties that accompany 
the primary diagnosis, eǀeŶ if these do Ŷot ƌeaĐh the ƌeƋuiƌed thƌeshold foƌ a ͞Đoŵoƌďid diagŶosis͟, 
needs scientific evaluation.  
Core ADHD symptoms that contribute to 
primary diagnosis 
Hyperactivity 
Impulsiveness 
Inattention 
Neurodevelopmental 
problems 
e.g. social communication, 
language, motor  
Cognitive impairments 
e.g. executive function, 
response inhibition 
Emotional  
e.g. emotional lability, irritability, 
anxiety 
 
links with later depression 
Behavioural 
e.g. aggression, headstrong/hurtful 
 
links with later antisocial behaviour 
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Five research questions 
 Using longitudinal patient and population-based cohort designs, what potentially modifiable 
factors optimise neurodevelopmental outcomes? Test causal effects through different 
research approaches (e.g. quasi-experimental and animal studies).  How does multi-morbidity affect neurodevelopmental outcomes and the threshold for 
treatment (e.g. longitudinal observational studies, treatment trials of complex patients)?  What is the natural history of neurodevelopmental disorders in the general population 
across ages (e.g. via longitudinal population cohort designs)?  How does social context (within and across countries) contribute to neurodevelopmental 
disorder associated impairments? For example, do longer-term outcomes and impairments 
differ across time and populations? This could be achieved by investigating outcomes in low 
and middle-income vs. high-income countries, for example.  Can we identify neurodevelopmental disorder subtypes that are clinically useful and that 
might transcend diagnostic boundaries and  predict functional outcomes? 
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